Related Experiment Videos
Double-blind dose reduction study of vigabatrin in complex partial epilepsy.
M R Sivenius1, A Ylinen, K Murros
1Department of Neurology, Kuopio University Central Hospital, Finland.
Epilepsia
|November 1, 1987
Summary
Gamma-vinyl GABA (GVG) effectively reduced complex partial seizures in epilepsy patients. Higher GVG dosages showed greater efficacy, with drowsiness as a common, diminishing side effect.
Area of Science:
- Neurology
- Pharmacology
Background:
- Epilepsy is a neurological disorder characterized by recurrent seizures.
- Complex partial seizures significantly impact patient quality of life.
Purpose of the Study:
- To evaluate the efficacy and tolerability of gamma-vinyl GABA (GVG) in epilepsy patients with complex partial seizures.
- To compare different dosages of GVG in a double-blind, placebo-controlled setting.
Main Methods:
- Seventy-five epilepsy patients received 3 g/day of GVG for 3 months.
- Responders entered a second phase with randomized GVG dosages (3 g/day vs. 1.5 g/day) under double-blind conditions.
Main Results:
- 54% of patients experienced a ≥50% reduction in seizure frequency.
- Median monthly seizure frequency decreased from 11.5 to 4.
- 3 g/day GVG was more effective than 1.5 g/day, though both reduced seizures compared to baseline.
- Drowsiness was the most frequent side effect, diminishing over time.
Conclusions:
- GVG demonstrates significant efficacy in reducing complex partial seizures.
- Higher GVG dosages (3 g/day) offer superior seizure control.
- GVG is generally well-tolerated, with manageable side effects.